288 related articles for article (PubMed ID: 25563411)
1. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.
Halpern B; Halpern A
Expert Opin Drug Saf; 2015 Feb; 14(2):305-15. PubMed ID: 25563411
[TBL] [Abstract][Full Text] [Related]
2. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
Chilton M; Dunkley A; Carter P; Davies MJ; Khunti K; Gray LJ
Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810
[TBL] [Abstract][Full Text] [Related]
3. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
5. Over-the-counter orlistat. A weight loss "Alli" or adversary on the horizon.
Anderson T
AWHONN Lifelines; 2006; 10(5):418-21. PubMed ID: 17069574
[No Abstract] [Full Text] [Related]
6. Safety and tolerability review of lorcaserin in clinical trials.
Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
[TBL] [Abstract][Full Text] [Related]
7. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
Nigro SC; Luon D; Baker WL
Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
9. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
Hurren KM; Dunham MW
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of lorcaserin for the treatment of obesity.
Berlie HD; Hurren KM
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
[TBL] [Abstract][Full Text] [Related]
12. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
14. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
15. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
16. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
19. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
Higgins GA; Fletcher PJ; Shanahan WR
Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
[TBL] [Abstract][Full Text] [Related]
20. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
Bays HE
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
